Company Overview - Cofoe Medical Technology Co., Ltd. specializes in the research, production, sales, and service of medical devices, with key products including blood glucose systems, uric acid systems, blood pressure monitors, and various other medical instruments and supplies [2]. Financial Performance - For Q1 2025, the company reported a revenue of 738 million yuan, representing a year-on-year decrease of 8.59%. The net profit was 91.43 million yuan, down 9.68% year-on-year, with a gross profit margin of 52.17% [2]. Market Position - As of June 24, Cofoe Medical's stock closed at 32.78 yuan, with a PE ratio of 22.70, while the average PE ratio for the medical device industry is 49.12, and the industry median is 36.07. Cofoe Medical ranks 50th in terms of PE ratio within its industry [1][3]. Capital Flow - On June 24, the net inflow of main funds into Cofoe Medical was 2.87 million yuan, with a total inflow of 4.85 million yuan over the past five days, indicating a generally positive capital flow trend [1].
可孚医疗收盘上涨1.30%，滚动市盈率22.70倍，总市值68.54亿元